Pediatrix Medical vs Progyny
MD and PGNY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MD and PGNY compare
Pediatrix Medical and Progyny are about the same size, with market caps of $2.5B and $2.8B.
On earnings, Pediatrix Medical is cheaper: it trades at 17.1× trailing earnings, against 33.5× for Progyny.
Progyny grew revenue faster over the last twelve months (5.5% versus 1.9% for Pediatrix Medical).
Pediatrix Medical keeps more of each dollar of sales as profit, with a net margin of 7.7% compared with 6.8% at Progyny.
Progyny scores higher on the StockData Score (20 against 10 for Pediatrix Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MD | PGNY |
|---|---|---|
| Size and price | ||
| Market cap | $2.5B | $2.8B |
| Share price | $31.45 | $36.50 |
| Change, 1 year | 39.3% | 54.5% |
| Change, 5 years | 21.8% | −38.5% |
| Beta (5Y) | 0.68 | 1.06 |
| Employees | – | 856 |
| StockData Score | ||
| Total score | 10 | 20 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 1 | 5 (better) |
| Performance score | 4 | 6 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 17.1× (better) | 33.5× |
| P/S | 1.3× (better) | 2.1× |
| P/B | 2.9× (better) | 6.8× |
| EV/EBITDA | 11.0× (better) | 19.7× |
| P/FCF | – | 15.6× |
| PEG | 0.49 (better) | 1.14 |
| FCF yield | – | 6.4% |
| Fair value | $29.34 | $38.32 |
| Margin of safety | −7.2% | 4.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.9% | 5.5% (better) |
| Revenue growth, 5Y average | 2.0% | 30.2% (better) |
| Net income growth (TTM) | −7.5% | 60.9% (better) |
| EPS growth (TTM) | −3.2% | 73.0% (better) |
| EPS growth, 5Y average | – | 6.7% |
| Profitability | ||
| Gross margin | – | 24.9% |
| Operating margin | 10.9% (better) | 9.4% |
| Net margin | 7.7% (better) | 6.8% |
| FCF margin | – | 13.4% |
| Return on equity | 17.2% | 18.7% (better) |
| Return on invested capital | 15.4% | 40.0% (better) |
| Financial health | ||
| Debt / equity | 0.68 (better) | 0.00 |
| Net debt / EBITDA | 0.64 | – |
| Interest coverage | 6.4× | – |
| Current ratio | 1.28 | 1.93 (better) |
| Altman Z-score | 2.47 | 10.00 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 8.5% | 11.2% (better) |
| Shareholder yield | 8.5% | 11.2% (better) |
| Ownership | ||
| Held by institutions | 107% | 103% |
| Held by insiders | 1.5% | 2.7% |
| Insider net buying, 12 months | −$1.4M (better) | −$14.1M |
| Short interest, % of float | 4.6% | 6.4% |
Go deeper
- MD stock overview
- MD income statement
- MD valuation and score
- PGNY stock overview
- PGNY income statement
- PGNY valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.